Reuters logo
5 months ago
BRIEF-Galectin Therapeutics says co had $15.4 mln of non-restricted cash and cash equivalents as of December 31 2016
March 28, 2017 / 12:41 PM / 5 months ago

BRIEF-Galectin Therapeutics says co had $15.4 mln of non-restricted cash and cash equivalents as of December 31 2016

March 28 (Reuters) - Galectin Therapeutics Inc

* Galectin Therapeutics Inc - as of December 31, 2016, company had $15.4 million of non-restricted cash and cash equivalents - sec filing

* Galectin Therapeutics - believes it has sufficient cash to fund currently planned operations and research and development activities through Dec 31

* Galectin Therapeutics Inc - top-line data readout of nash-cx trial remains on track for early December 2017

* Galectin Therapeutics Inc - positive results in studies of gr-md-02 for patients with serious skin diseases Source text - bit.ly/2nHHEas Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below